IL173944A0 - Compositions for treating pathologies that necessitate suppression of gastric acid secretion - Google Patents

Compositions for treating pathologies that necessitate suppression of gastric acid secretion

Info

Publication number
IL173944A0
IL173944A0 IL173944A IL17394406A IL173944A0 IL 173944 A0 IL173944 A0 IL 173944A0 IL 173944 A IL173944 A IL 173944A IL 17394406 A IL17394406 A IL 17394406A IL 173944 A0 IL173944 A0 IL 173944A0
Authority
IL
Israel
Prior art keywords
necessitate
suppression
compositions
gastric acid
acid secretion
Prior art date
Application number
IL173944A
Other languages
English (en)
Original Assignee
Vecta Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vecta Ltd filed Critical Vecta Ltd
Publication of IL173944A0 publication Critical patent/IL173944A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
IL173944A 2003-08-27 2006-02-26 Compositions for treating pathologies that necessitate suppression of gastric acid secretion IL173944A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49793003P 2003-08-27 2003-08-27
US54431804P 2004-02-17 2004-02-17
PCT/IB2004/002745 WO2005020879A2 (fr) 2003-08-27 2004-08-25 Compositions pour le traitement de pathologies qui necessitent la suppression des secretions d'acide gastrique

Publications (1)

Publication Number Publication Date
IL173944A0 true IL173944A0 (en) 2006-07-05

Family

ID=34278571

Family Applications (1)

Application Number Title Priority Date Filing Date
IL173944A IL173944A0 (en) 2003-08-27 2006-02-26 Compositions for treating pathologies that necessitate suppression of gastric acid secretion

Country Status (8)

Country Link
EP (1) EP1658089A4 (fr)
JP (1) JP2007503427A (fr)
KR (1) KR20060083198A (fr)
AU (1) AU2004268446A1 (fr)
CA (1) CA2536906A1 (fr)
IL (1) IL173944A0 (fr)
RU (1) RU2006109357A (fr)
WO (1) WO2005020879A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007506730A (ja) * 2003-09-24 2007-03-22 ベクタ・リミテッド ペンタガストリンを含む胃酸分泌刺激用経口組成物
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
MY151470A (en) * 2005-12-28 2014-05-30 Takeda Pharmaceutical Controlled release solid preparation
SG184754A1 (en) * 2005-12-28 2012-10-30 Takeda Pharmaceutical Controlled release solid preparation
RU2467747C2 (ru) 2006-07-25 2012-11-27 Векта Лтд. Композиции и способы для ингибирования секреции желудочной кислоты с использованием производных малых дикарбоновых кислот в сочетании с ppi
MX2010001071A (es) * 2007-07-27 2010-03-09 Depomed Inc Formas de dosificacion retentivas gastricas pulsatiles.
EP4311542A1 (fr) * 2022-07-27 2024-01-31 Roquette Freres Formes posologiques à languette flottante

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL77186A0 (en) * 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
JP3181062B2 (ja) * 1991-01-31 2001-07-03 帝國製薬株式会社 下部消化管崩壊経口製剤
BR9915442A (pt) * 1998-11-17 2001-08-07 Hickory Specialties Inc Método para a cobertura de um produto de alimento com colágeno
AU5060499A (en) * 1999-08-04 2001-03-05 Ranbaxy Laboratories Limited Hydrodynamically balanced oral drug delivery system
IL152289A0 (en) * 2002-10-14 2003-05-29 Vectabiotics Ltd Method and composition for inhibiting h.pylori infection in a mammalian tissue

Also Published As

Publication number Publication date
WO2005020879A3 (fr) 2005-05-19
CA2536906A1 (fr) 2005-03-10
JP2007503427A (ja) 2007-02-22
EP1658089A2 (fr) 2006-05-24
EP1658089A4 (fr) 2007-03-14
RU2006109357A (ru) 2007-10-10
WO2005020879A2 (fr) 2005-03-10
AU2004268446A1 (en) 2005-03-10
KR20060083198A (ko) 2006-07-20

Similar Documents

Publication Publication Date Title
IL173944A0 (en) Compositions for treating pathologies that necessitate suppression of gastric acid secretion
PL376178A1 (en) Gastric acid secretion inhibiting composition
ZA200709745B (en) Compositions and methods for inhibiting gastric acid secretion
IL152127A0 (en) Probiotic compositions for the treatment of inflammatory bowel disease
GB0321607D0 (en) Manufacture of pharmaceutical compositions
GB0221688D0 (en) Compositions for wound treatment
IL175535A0 (en) Compositions for treatment of neurodegenerative diseases
IL173930A0 (en) Pharmaceutical compositions containing forms of r-baclofen
HK1191861A1 (zh) 胃酸分泌的快速作用抑制劑
AU2003248786A8 (en) Compositions comprising panthetine for the treatment of dyslipidemia
IL179337A0 (en) Pharmaceutical compositions for the treatment of pruritus
PL366653A1 (en) Method for manufacture of polyorganooxosilane compositions
ZA200709852B (en) Spiro-benzimidazoles as inhibitors of gastric acid secretion
ZA200704775B (en) Compositions for treatment of ear infections
EP1765761A4 (fr) Nouveaux analogues de 3-o-acetyl-11-ceto-beta-acide boswellique
EP1680104A4 (fr) Traitement de l'ostheoarthrite: composition contenant de l'apigenine en tant qu'agent chondroregenerateur
AU2003216400A8 (en) Compounds for treatment of copper overload
AU2003225956A8 (en) Apparatus for automatic application of compositions to the skin
GB2355657B (en) Inhibitors Of Gastric Acid Secretion
HUP0303779D0 (en) Pharmaceutical compositions for the treatment of sclerosis multiplex
PL1687006T3 (pl) Kompozycje farmaceutyczne do leczenia zaburzeń czynności nerek
AU2003244690A8 (en) Compositions for treating digestive functional pathologies
EP1541548A4 (fr) Procede d'oxamidination de composes carbonyle
EP1663282A4 (fr) Compositions a administration par voie orale, destinees a la stimulation de la secretion d'acide gastrique et comportant de la pentagastrine
GB0313630D0 (en) Compositions for the enhanced treatment of depression